POST Online Media Lite Edition



 

Targovax appoints Damian Marron as chairman

Christian Fernsby |
Oslo, Norway - Targovax, a clinical stage biotechnology company, announces that its nomination committee has nominated Damian Marron for election as chairman of the board.

Article continues below




Mr. Marron is an experienced non-executive director, corporate advisor and life science executive with a successful track record of value creation through public and venture capital financing, portfolio planning, M&A, licensing agreements as well as R&D collaborations, both as an executive and in advisory roles.

Mr. Marron has notably specialized in immuno-oncology, cell therapy and orphan diseases.

Mr. Marron is currently Non-Executive Director at Bone Therapeutics a clinical stage, regenerative medicine company listed on Euronext and Resolys Bio, a private, late pre-clinical US startup.

He is also Head of Biopharma with Treehill Partners, a global pure-play healthcare advisory firm.

 LATEST MOVES FROM Norway 

Cermaq makes senior management appointments
Aker Solutions appoints Ole Martin Grimsrud as CFO
Aker BP appoints Marit Blaasmo as senior vice president
Nordic Nanovector appoints Lisa Rojkjaer as chief medical officer
Targovax appoints Oystein Soug as CEO